問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3158Cases

2025-10-01 - 2028-04-30

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-07-01 - 2030-06-30

Phase III

Not yet recruiting
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

  • Condition/Disease

    Psoriatic Arthritis

  • Test Drug

    錠劑

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2025-10-15 - 2028-10-31

Phase II

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-07-01 - 2028-12-31

Others

Active
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)Metastatic Breast Cancer

  • Condition/Disease

    Metastatic Breast Cancer

  • Test Drug

    膜衣錠 膜衣錠 預充填式注射劑 膜衣錠 膜衣錠 膜衣錠 膜衣錠 持續釋放膜衣錠 膜衣錠

Participate Sites
2Sites

Not yet recruiting2Sites

2025-10-15 - 2031-11-14

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-07-01 - 2028-12-31

Phase III

Not yet recruiting
A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    膜衣錠 錠劑

Participate Sites
10Sites

Not yet recruiting10Sites

2026-07-01 - 2029-12-30

Phase III

Not yet recruiting
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (Embold)

  • Condition/Disease

    Weight Management

  • Test Drug

    膜衣錠

Participate Sites
10Sites

Not yet recruiting10Sites

2025-10-31 - 2029-02-04

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting5Sites

2025-11-01 - 2030-06-07

Others

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting1Sites

2026-08-01 - 2028-12-31

Phase III

Not yet recruiting
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)

  • Condition/Disease

    Obesity or Overweight

  • Test Drug

    注射液

Participate Sites
11Sites

Not yet recruiting1Sites

1 2 3 4 5 316
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB